From lungs to nasal polyps: Sanofi finds success with 2-in-1 inflammation blocker

Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...
Clinical Trials Arena on MSN

Sanofi’s bispecific scores in respiratory diseases but fails in eczema

Sanofi’s lunsekimig met its endpoints in asthma and CRSwNP but missed the primary endpoint in eczema.

Sanofi immune drug hopeful posts mixed results in mid-stage tests

Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...